Interleukin-6 Levels Predict Severe Relapses in ANCA Vasculitis Patients on Rituximab, Study Reports
Although serum levels of the pro-inflammatory molecule interleukin (IL)-6 do not predict who will achieve complete remission, increases during periods of no disease activity are associated with subsequent severe relapses in patients with ANCA-associated vasculitis (AAV) on rituximab, according to an exploratory study. The research, “The…